BW-20507 by Argo Biopharma Australia for Hepatitis B: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BW-20507 overview

BW-20507 is under development for the treatment of chronic hepatitis B virus (HBV) infection. The therapeutic candidate is administered through subcutaneous route in the form of solution.

Argo Biopharma Australia overview

Argo Biopharma Australia (Argo Biopharma) is an healthcare service provider which is specialized in research, development and offers other related services. Argo Biopharma is headquartered in Adelaide, South Australia, Australia.

For a complete picture of BW-20507’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.